Virtus Family Office’s BioNTech BNTX Stock Holding History

Virtus Family Office’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,818	Closed	-$216K	–	42
2024 Q3	$216K	Buy	+1,818	New	+$167K	0.29%	46

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Virtus Family Office's BNTX Position: Q4 2024 in Review

Virtus Family Office sold out of BioNTech (BNTX) in Q4 2024, closing a stake of 1,818 shares — an estimated $216K sold.

Virtus Family Office first reported a position in BNTX in Q3 2024 and held it in 1 quarter. The position peaked at $216K in Q3 2024. 303 funds tracked by Wall St. Rank hold BNTX as of Q4 2024.

Virtus Family Office reported no remaining BioNTech position as of Q4 2024 after selling out during the quarter.
Virtus Family Office sold 1,818 BioNTech shares in Q4 2024, an estimated $216K.
Virtus Family Office first reported a position in BioNTech in Q3 2024 and held it in 1 quarter.
Virtus Family Office's BioNTech position peaked at $216K in Q3 2024.
303 funds tracked by Wall St. Rank held BioNTech as of Q4 2024.

Based on Virtus Family Office's 13F filing for Q4 2024, filed 11 Feb 2025.